Tag: DCB

Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy

Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...

VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion...

FDA official delivers government agency’s early reaction to latest contentious meta-analysis...

HOLLYWOOD, Fla.—A Food and Drug Administration (FDA) official delivered a talk which represents the government agency’s earliest public reaction to the latest meta-analysis suggesting...
x-ray image below knee amputation or BKA amputation

Deploying robust, detailed SVS VQI data to help better define role...

In December 2018, the Journal of the American Heart Association published “Risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal...

New meta-analysis finds ‘no observed difference’ in mortality between paclitaxel and...

February 2020 brings another paclitaxel device meta-analysis of randomized controlled trials in chronic limb-threatening ischemia (CLTI) patients. Krystal Dinh, BMed, of Westmead Hospital, Sydney,...
x-ray image below knee amputation or BKA amputation

Hotly-contested meta-analysis suggests a higher risk of death or amputation at...

A new meta-analysis, just published in the Journal of Vascular and Interventional Radiology (JVIR), suggests significantly reduced amputation-free survival at one year when paclitaxel-coated...